Otezla
Amgen’s Otezla holds its ground against BMS’ Sotyktu in oral plaque psoriasis market, leaving room for J&J’s potential game-changer
Anika Sharma
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
Amgen Takes a Playful Approach with Otezla Advertisement Amid Growing Competition in the Psoriasis Market
SG Tylor
Amgen, a major biotech company, has taken an innovative approach to connect with psoriasis patients by using humor in their ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
SG Tylor
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IV IMMpulse study in ...
